Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lifecare AS ( (DE:LFC0) ) has provided an update.
Lifecare ASA has received approval from the Regional Committee for Medical and Health Research Ethics in Norway for its first-in-human trial of an implantable CGM sensor, marking a significant milestone towards regulatory testing. The trial, aimed at assessing safety and accuracy in type 1 diabetes patients, will be conducted in Norway and Germany, pending final approval from the Norwegian Medicines Agency. This progress, alongside successful technical verifications, underscores Lifecare’s advancement towards regulatory readiness and clinical evaluation of its CGM technology.
More about Lifecare AS
Lifecare ASA is a MedTech company specializing in the development of next-generation Continuous Glucose Monitoring (CGM) technology for diabetes management. The company focuses on creating sensor technology capable of identifying and monitoring a wide range of analytes and molecules in both humans and pets.
Average Trading Volume: 59,263
Current Market Cap: NOK87.68M
See more data about LFC0 stock on TipRanks’ Stock Analysis page.